{"database":"biostudies-other","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["73(9)"],"submitter":["Sinn P"],"journal":["Geburtshilfe und Frauenheilkunde"],"pagination":["932-940"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3859151"],"abstract":["Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, Genomic Grade Index®) and IHC risk scores (Mammostrat® and IHC4), and discuss the current evidence of their clinical use."],"repository":["biostudies-other"],"pmcid":["PMC3859151"],"data_source":["Europe PMC"],"pubmed_authors":["Marme F","Lebeau A","Aulmann S","Sinn P","Kreipe H","Schneeweiss A","Wirtz R","Schott S","Varga Z"],"additional_accession":[]},"is_claimable":false,"name":"Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.","description":"Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, Genomic Grade Index®) and IHC risk scores (Mammostrat® and IHC4), and discuss the current evidence of their clinical use.","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Sep","modification":"2019-03-27T01:18:18Z","creation":"2019-03-27T01:18:18Z"},"accession":"S-EPMC3859151","cross_references":{"pubmed":["24771945"],"nct":["NCT00544765"],"doi":["10.1055/s-0033-1350831 "]}}